Canadian Drug Facility Cited for Contamination Risks

Drug Industry Daily
A A
Contract drug manufacturer Jubilant HollisterStier drew a Form 483 after the FDA observed contamination risks at the firm’s Kirkland, Quebec facility.

To View This Article:

Login

Subscribe To Drug Industry Daily